Sera Prognostics, Inc. SERA

SERA Company Overview

Sera Prognostics, Inc. is a U.S.-based biotechnology company focused on developing and commercializing blood-based proteomic tests intended to improve maternal and neonatal health outcomes. The company operates within the women’s health, diagnostics, and precision medicine industries, with a primary emphasis on predicting risks associated with preterm birth and pregnancy complications. Its principal commercial product is the PreTRM test, a commercially available maternal blood test designed to identify pregnant individuals at increased risk of spontaneous preterm birth before clinical symptoms emerge. Revenue generation has historically been tied to testing services, collaboration arrangements, and research-related activities, although the company remains in a growth and commercialization stage.

The company was founded in 2008 and is headquartered in Salt Lake City, Utah. Sera Prognostics evolved from a research-focused proteomics company into a commercial-stage diagnostics business centered on predictive biomarker technologies for pregnancy management. The company’s strategic positioning is based on its proprietary proteomics and bioinformatics platform, large-scale maternal health datasets, and clinical validation efforts aimed at demonstrating the economic and clinical utility of early risk prediction. Public filings and company disclosures indicate that the company seeks to differentiate itself through clinically validated biomarker discovery and integration with obstetric care pathways.